Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Most tumor-infiltrating lymphocyte (TIL) studies and therapies have focused on tumors with high T-cell infiltration and mutational burden. Glioblastoma (GBM) represents a challenging indication for TIL therapy because of its limited T-cell infiltration and low mutational burden. We investigated whether targeted enrichment of tumor-reactive T cells using CD137-based selection could enable robust, clinical-scale production of TIL products from GBM.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
